US2016304609A1PendingUtilityA1
Humanized and chimeric monoclonal antibodies to cd47
Assignee: UNIV LELAND STANFORD JUNIORPriority: May 14, 2010Filed: Jun 7, 2016Published: Oct 20, 2016
Est. expiryMay 14, 2030(~3.8 yrs left)· nominal 20-yr term from priority
A61P 35/02A61P 35/00A61P 37/04C07K 2317/732C07K 16/2896C07K 16/2803C07K 2317/94C07K 2317/24C07K 2317/73C07K 2317/56C07K 2317/565C07K 2317/567G01N 33/6872C07K 2317/70C07K 2317/734C07K 2317/76C07K 2317/71C07K 16/465
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated chimeric or humanized antibody that specifically binds to human CD47, and comprises at least one CDR sequence as set forth in SEQ ID NO:3-8, SEQ ID NO:20-25; SEQ ID NO:28-33 or SEQ ID NO:61-66.Join the waitlist — get patent alerts
Track US2016304609A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.